

Lybridos Food effect study

Voedsel effect onderzoek naar Lybridos

Gepubliceerd: 23-10-2014 Laatste bijgewerkt: 15-05-2024

Primary objective 1. To determine the effect of food on the pharmacokinetics of buspirone administered as the Lybridos formulation Secondary objective 1. To evaluate the safety and tolerability of a single dose of Lybridos under fasted and fed...

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON22366

Bron

Nationaal Trial Register

Aandoening

Seksueel functioneren, Seksuele disfunctie

Ondersteuning

Primaire sponsor: EB FSD

Overige ondersteuning: EB FSD

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

90% CI ratio for both AUC_{0-inf} and C_{max}

Toelichting onderzoek

Achtergrond van het onderzoek

A total of 18 subjects receive the investigational drug. During the 2 experimental days (where bloodsampling for PK analysis will take place), subjects receive Lybridos under Fed and Fasted conditions in random order. Subjects visit the site a total of 8 times: 1 screening visit, 1 experimental day for two times in a crossover (consisting of an admission, day 1 and day 2) and 1 final follow up visit.

Doel van het onderzoek

Primary objective

1. To determine the effect of food on the pharmacokinetics of buspirone administered as the Lybridos formulation

Secondary objective

1. To evaluate the safety and tolerability of a single dose of Lybridos under fasted and fed conditions

Onderzoeksopzet

A total of 18 subjects receive the investigational drug. During the 2 experimental days (where bloodsampling for PK analysis will take place), subjects receive Lybridos under Fed and Fasted conditions in random order. Subjects visit the site a total of 8 times: 1 screening visit, 1 experimental day for two times in a crossover (consisting of an admission, day 1 and day 2) and 1 final follow up visit.

Onderzoeksproduct en/of interventie

Lybridos 2 gifts

Contactpersonen

Publiek

Companion Diagnostics BV
Louis Armstrongweg 78

J. Gerritsen

Almere 1311 RL
The Netherlands

Wetenschappelijk

Companion Diagnostics BV
Louis Armstrongweg 78

J. Gerritsen
Almere 1311 RL
The Netherlands

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Provision of informed consent
2. Females between 18 and 55 years of age (both inclusive)
3. Healthy based on medical history, physical examination (including vital signs), electrocardiogram, laboratory values
4. Body mass index (BMI) ≥ 18 kg/m² and ≤ 30 kg/m²
5. Venous access sufficient to allow blood sampling as per protocol

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Cardiovascular conditions

1. Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg.
2. Systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg

Gynaecological and obstetric conditions

3. Use of oral contraceptives containing anti-androgens (e.g. crypteron acetate) or anti

(androgenic) progestogens (drospiridone, dienogest, chlormadinone acetate and norgestrel)

4. Use of any hormone replacement therapy (HRT) containing more than 50 µg/day of estrogen

5. Pregnancy (note: an urine pregnancy test will be performed in all women prior to the administration of study medication)

6. Lactating or delivery in the previous 6 months

7. Perimenopausal status (cycle shortening/irregular menstrual bleeding in the last 12 consecutive months and/or occurrence of vasomotor symptoms (e.g. hot flashes, night contraceptive sweating) in combination with elevated FSH levels (>40 IU/L) for women age 40 onwards; in women with a history of hysterectomy, perimenopausality can be assessed by FSH levels (>40 IU/L) and/or vasomotor symptoms)

General

8. Use of any drugs from two weeks prior to admission to the research unit until the follow-up visit, except for allowed oral contraceptives and pain relief (e.g. paracetamol up to 1.5 g per day)

9. Known or suspected hypersensitivity to any of the components of the formulation

10. Liver function tests (i.e., alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin) significantly above the upper limit of normal (ULN) at repeated measures

11. Any clinically significant history or any other disease or disorder- gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric, or metabolic as judged by the medical investigator

12. Smoking

13. Unwilling or unable to refrain from consuming grapefruit juice, star fruit and St. Johns Wort 24 hours before and after intake of medication

14. Current regular use of any illicit drugs or history of excessive drinking within 3 months prior to admission to the research unit and/or unwilling or unable to refrain from products containing alcohol from 24 hours before admission and during the stay in the research unit

15. Donation of blood within 3 months prior to admission to the research unit

16. Positive serology test for hepatitis B serum antigen (HBsAg), anti-hepatitis A virus (HAV) (IgM), anti-hepatitis C virus (HCV) or anti human immunodeficiency virus (HIV) 1+2

17. Subjects who, in the opinion of the investigator, are not likely to complete the trial for any reason
18. Participation in any clinical study within 1 month prior to the expected date of enrolment into the study.
19. Employees of the sponsor or CRO involved in the study

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Cross-over
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	26-01-2015
Aantal proefpersonen:	18
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies	
Datum:	23-10-2014
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 41098

Bron: ToetsingOnline

Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL4717
NTR-old	NTR4862
CCMO	NL50357.056.14
OMON	NL-OMON41098

Resultaten